B

Vertex Pharmaceuticals Incorporated VRTX

$516.34 $3.080.60% NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
EPS (TTM)
Access our Premium Ratings
Get Access

Rating

Reward
Risk

Rating Factors

Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index

Company Overview

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious diseases. The company operates primarily within the biotechnology and pharmaceutical industries, with a strong emphasis on genetic and rare diseases. Vertex’s business model centers on developing transformative therapies that address the underlying causes of disease rather than symptomatic treatment.

Vertex is best known for its leadership in treatments for cystic fibrosis (CF), where it has developed multiple approved therapies that have reshaped the standard of care. Its primary revenue drivers are CF modulators, alongside a growing pipeline targeting pain, sickle cell disease, beta thalassemia, and type 1 diabetes. Founded in 1989, Vertex evolved from a research-focused biotech into a profitable, fully integrated pharmaceutical company following the commercial success of its CF franchise in the 2010s.

Data compiled by narrative technology. May contain errors.
Sector

Income Statement

Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)

Balance Sheet

Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)

Filings

Filing Date
Tuesday, August 4, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 2 and 6 (est)

Price History

Loading...
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High

Valuation

Market Cap
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)

Dividends and Shares

Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--

Corporate Info

Phone Number
617 341 6100
Address
50 Northern Avenue
Boston, MA 02210
Country
Year Founded

Headlines

9/16/2026 - Zacks Investment Research